Xeljanz — Competitive Intelligence Brief

Xeljanz (tofacitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

marketed JAK inhibitor Janus kinase (JAK) enzymes Immunology

Target snapshot

Xeljanz (tofacitinib) — Pfizer. Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xeljanz TARGET	tofacitinib	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Pf-07293893	pf-07293893	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) pathway	Not available
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
JAK Inhibitor	JAK Inhibitor	Fred Hutchinson Cancer Center	marketed	JAK inhibitor	JAK1, JAK2, JAK3, and/or TYK2
Abrocitinib Suspension F1	abrocitinib-suspension-f1	Pfizer	marketed	JAK inhibitor	JAK1
Tofacitinib with methotrexate	Tofacitinib with methotrexate	Pfizer	marketed	JAK inhibitor + DMARD	JAK1, JAK3 (tofacitinib); dihydrofolate reductase (methotrexate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

1. Pfizer · 19 drugs in this class
2. Aclaris Therapeutics, Inc. · 2 drugs in this class
3. Beijing Friendship Hospital · 2 drugs in this class
4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
5. CAGE Bio Inc. · 1 drug in this class
6. CTI BioPharma · 1 drug in this class
7. Celgene · 1 drug in this class
8. Fred Hutchinson Cancer Center · 1 drug in this class
9. LEO Pharma · 1 drug in this class
10. McMaster University · 1 drug in this class